Poland's pharmaceutical and biotechnology sector represents one of Europe's most dynamic and cost-competitive manufacturing ecosystems, combining EU GMP-certified production capabilities with significant cost advantages over Western European counterparts. The total pharmaceutical market exceeds €11 billion, making Poland the largest pharma market in Central and Eastern Europe and the 5th largest drug market in the EU by value. With pharmaceutical exports reaching €4.8 billion in 2023 (up 9% year-on-year) and medical device exports at a record €5.65 billion, Poland has emerged as a serious export-oriented manufacturing hub. The sector encompasses approximately 490 companies — from generics giants (Polpharma, Adamed) to innovative biotech firms (Ryvu Therapeutics, Celon Pharma, Mabion) and world-class CDMO providers (Rezon Bio, Polpharma API) — employing over 26,000 professionals across the pharmaceutical value chain. International buyers seeking reliable, EU-compliant pharma partners will find in Poland a unique combination of cost efficiency (30–40% savings vs. Germany/Switzerland), regulatory alignment, innovation capacity, and supply chain proximity.
Strategic Insight: Poland's pharmaceutical sector is undergoing a structural transformation from a primarily generics-focused market to a diversified innovation ecosystem. The combination of competitive CDMO pricing, EMA-aligned regulatory frameworks, and a growing biotech pipeline positions Poland as the emerging "pharma nearshore" of choice for European and North American companies looking to de-risk Asian supply chains while maintaining cost efficiency. Key indicators — including export growth, VC investment flows, and the launch of dedicated CDMO entities like Rezon Bio — suggest this trend will accelerate through 2026–2028.
The Polish pharmaceutical market's evolution over the past two decades represents one of Central Europe's most significant industrial success stories. From a post-communist pharmaceutical landscape dominated by state-owned enterprises producing basic generics, Poland has built a diversified sector that now spans the entire pharmaceutical value chain — from API synthesis and generic drug manufacturing through biosimilar development, contract research, and cutting-edge biotech innovation. The total pharmaceutical market value has more than doubled since 2016, with export values growing from approximately €3.8 billion to over €9.5 billion (pharmaceuticals plus medical devices combined) in 2023.
Generics form the backbone of Poland's pharmaceutical industry, accounting for approximately 70% of the domestic market by volume. Poland is home to several of Europe's largest generics manufacturers. Polpharma, the market leader, has over 70 years of manufacturing experience and operates cGMP-compliant, FDA-approved facilities producing a broad portfolio of solid oral dosage forms, sterile products, and APIs. Adamed, another domestic champion, holds nearly 200 patents worldwide and is consistently at the forefront of Polish patent applicants in the European Patent Office index. Other significant players include Polfa Tarchomin (increasingly focused on API production), US Pharmacia, and Zakłady Farmaceutyczne Polpharma. The generics segment is characterised by a strong cost-to-quality ratio, with Polish manufacturers competing effectively against Indian and Chinese generics producers for European market share, particularly where supply chain reliability and regulatory alignment are priorities.
Poland's API manufacturing sector has emerged as a strategic asset in the post-pandemic European pharmaceutical landscape. With the EU's Pharmaceutical Strategy emphasising reduced dependence on Asian API supply chains, Polish API producers are increasingly well-positioned to capture nearshoring demand. The sector includes approximately 60 companies, with Polpharma's API division being the largest domestic producer — operating cGMP-compliant, FDA-approved facilities capable of producing complex small-molecule APIs, intermediates, and custom-synthesised molecules. Polfa Tarchomin has also pivoted strategically toward API production, recognising the higher margins and less saturated competitive landscape compared to finished dosage forms. Polish API manufacturers typically offer 35–50% cost savings compared to German or Swiss producers while maintaining identical regulatory standards under the EU GMP framework.
The biosimilars segment represents one of the most dynamic growth areas within Poland's pharmaceutical sector. Mabion, a publicly listed company, has been developing a biosimilar version of rituximab (a monoclonal antibody used in blood cancers and autoimmune disorders) and has partnered with Novavax to support vaccine antigen production for international markets. The most significant development in this space has been the strategic transformation of Polpharma Biologics, which in 2025 split into two entities: Polpharma Biologics (relocated to Switzerland for its biosimilar commercial operations) and Rezon Bio, a newly launched European CDMO for biologics based in Poland. Rezon Bio operates two facilities — in Gdańsk (EMA certified, FDA approved) and Warsaw-Duchnice (EMA certified, FDA licensing planned) — offering end-to-end services from cell line development through GMP manufacturing and commercial supply. The company's infrastructure is based on single-use systems for faster product turnover and accelerated delivery, representing a significant addition to Europe's biologics CDMO capacity.
Poland's CDMO sector has been growing rapidly, driven by the European nearshoring trend and the country's competitive cost structure combined with EU GMP compliance. The sector includes over 60 companies offering a spectrum of services from small-molecule manufacturing and formulation development to biologics production and fill-and-finish operations. Polpharma Group's CDMO division is the largest player, leveraging over 70 years of pharmaceutical manufacturing experience and FDA-approved facilities. Rezon Bio (launched 2025 from Polpharma Biologics) has positioned itself explicitly to disrupt the European CDMO landscape, combining Polish cost competitiveness with high-end biologics manufacturing capabilities. Other notable CDMOs include SciencePharma (regulatory consulting and pharmaceutical development), specialist packaging and serialisation providers, and a growing number of companies offering integrated preclinical-to-commercial services. The CDMO segment is particularly export-oriented, with 60–70% of output serving international clients.
Poland has established itself as one of Central Europe's leading destinations for clinical research, with over 40 contract research organisations providing services spanning Phase I through Phase IV clinical trials, bioanalytical method development and validation, pharmacovigilance, and regulatory affairs consulting. The country's large, treatment-naïve patient population, competitive per-patient costs (50–60% lower than Germany or Switzerland for Phase II oncology trials), and experienced clinical investigators make it an attractive location for international sponsors. The Polish Medical Research Agency (ABM), established specifically to support clinical research, provides dedicated funding for investigator-initiated trials and fosters collaboration between academic medical centres and industry. SciencePharma, one of the leading Polish pharmaceutical consultancies, has prepared over 600 regulatory dossiers for medicinal products, demonstrating the depth of regulatory expertise available in the market.
The medical devices and diagnostics segment is Poland's largest life sciences export category, with exports reaching a record €5.65 billion in 2023. The sector comprises approximately 5,000 entities including manufacturers, importers, and distributors, according to a 2024 PARP report. Two categories dominate exports: orthopaedic equipment, apparatus, prostheses, and hearing aids (€2.5 billion in exports), and medical and veterinary instruments (€1.4 billion). Innovation in this segment is notable — Scope Fluidics has developed microfluidic-based diagnostic systems for rapid point-of-care testing, BrainScan has created an AI-powered radiology tool achieving 90% diagnostic accuracy, and the SmartHeal startup has patented an intelligent wound dressing with integrated pH sensors, winning the James Dyson Award in 2022. Approximately 13% of all Polish startups operate in the healthtech sector, and 64% of healthcare startups are developing AI and machine learning applications.
| Segment | Revenue (€M) | Companies | Export Share | Growth Trend | Key Players |
|---|---|---|---|---|---|
| Generics | €4,800–5,200 | 120+ | 35–40% | Stable (+3–5%) | Polpharma, Adamed, US Pharmacia |
| APIs | €1,200–1,500 | 60+ | 55–65% | Growing (+7–10%) | Polpharma API, Polfa Tarchomin |
| Biosimilars / Biologics | €800–1,100 | 25–30 | 45–55% | High growth (+12–18%) | Mabion, Rezon Bio, Bioton |
| CDMO | €900–1,200 | 60+ | 60–70% | High growth (+10–15%) | Polpharma CDMO, Rezon Bio |
| CRO | €400–550 | 40+ | 70–80% | Growing (+8–12%) | SciencePharma, Pharma Professionals |
| Diagnostics / MedTech | €1,500–1,800 | 150+ | 40–50% | Growing (+6–9%) | Scope Fluidics, BrainScan, Synektik |
| Nutraceuticals | €600–800 | 80+ | 25–35% | Growing (+5–8%) | Multiple SMEs |
| Total | €10,200–12,150 | 490+ | ~44% |
Sources: PAIH 2025, GUS, IBISWorld 2026, IQVIA, Statista, ITC trade data. Figures are estimates for 2025. Company counts include overlaps across segments.
Poland's pharmaceutical manufacturing infrastructure has undergone significant modernisation over the past decade, driven by sustained investment from both domestic companies and international players. The country now hosts a comprehensive range of manufacturing capabilities — from high-volume solid oral dosage form production and sterile injectables to advanced biologics manufacturing and sophisticated API synthesis. The manufacturing landscape benefits from Poland's membership in the EU, which ensures regulatory alignment with European Medicines Agency standards and provides access to the single market, combined with significantly lower operating costs that make Poland one of the most cost-effective pharmaceutical manufacturing locations in the EU.
Poland's strength in solid oral dosage (OSD) manufacturing is rooted in decades of generics production. The country's OSD facilities are equipped with modern high-speed tableting lines, granulation equipment, film-coating systems, and blister packaging lines meeting EU GMP Annex 1 (where applicable) and Annex 15 requirements. Production capacities range from pilot-scale (thousands of units) to large-scale commercial production (billions of tablets per year across the major manufacturers). Polpharma alone operates multiple manufacturing sites capable of producing a wide range of immediate-release, modified-release, and enteric-coated formulations. Quality systems typically include in-process controls using near-infrared spectroscopy, dissolution testing, content uniformity verification, and statistical process control — all standard for EU GMP-certified facilities.
The biologics manufacturing segment has seen the most dramatic capability upgrades in recent years. Rezon Bio's two facilities (Gdańsk and Warsaw-Duchnice) represent state-of-the-art biologics manufacturing infrastructure with mirrored capabilities enabling seamless technology transfer and flexible scale-up. The infrastructure is based on single-use systems — including single-use bioreactors, mixing systems, and chromatography columns — which enable faster product turnover, reduced cross-contamination risk, and accelerated delivery timelines. Development platforms include AMBR (Automated Micro-Bioreactor) systems optimised to shorten early development cycles and de-risk scale-up. The Gdańsk facility holds EMA certification and FDA approval, while the Duchnice site is EMA certified with planned FDA licensing. Mabion's manufacturing facility in Łódź is equipped for monoclonal antibody production at clinical and commercial scales.
API manufacturing in Poland covers a broad spectrum of capabilities, from multi-step chemical synthesis of complex small molecules to fermentation-based production processes. Polpharma's API facilities have been inspected and approved by both EMA and FDA, manufacturing active substances for both internal use and third-party supply. Polfa Tarchomin has invested in a dedicated API production facility, strategically pivoting from finished dosage forms toward the higher-margin API supply market. These facilities typically feature multipurpose reactors, distillation and crystallisation equipment, drying technologies, and dedicated analytical laboratories with HPLC, GC-MS, and NMR capabilities. Environmental management systems meeting ISO 14001 standards are increasingly common, reflecting both regulatory expectations and customer requirements.
Quality assurance in Polish pharmaceutical manufacturing operates within the comprehensive EU GMP framework, with regular inspections by Poland's Chief Pharmaceutical Inspectorate (GIF). The typical quality infrastructure at a Polish pharma manufacturing site includes: a fully equipped quality control laboratory with analytical chemistry capabilities (HPLC, UPLC, GC, Karl Fischer titration, dissolution testing), a microbiology laboratory for sterility testing, endotoxin testing, and environmental monitoring, qualified stability chambers for ICH-compliant stability studies (25°C/60% RH, 30°C/65% RH, 40°C/75% RH), and validated computer systems for batch record management, deviation tracking, and CAPA (corrective and preventive action) management. ISO 9001:2015 certification is held by 85–90% of exporting pharmaceutical companies, while ISO 13485:2016 is standard for medical device manufacturers. Good Laboratory Practice (GLP) compliance is mandatory for non-clinical safety testing facilities.
| Capability | Technology Level | Capacity Range | Key Certifications |
|---|---|---|---|
| Solid Oral Dosage | Advanced (high-speed, multi-format) | Millions–Billions units/year | EU GMP, ISO 9001 |
| Sterile Injectables | Modern (isolator, RABS technology) | Clinical to commercial scale | EU GMP Annex 1, FDA (select) |
| Biologics / mAb | State-of-the-art (single-use, AMBR) | Up to 2,000L SUB scale | EU GMP, EMA, FDA |
| API Synthesis | Advanced (multi-step, cGMP) | kg to multi-tonne | EU GMP, FDA, CEP/EDMF |
| Pharmaceutical Packaging | Modern (serialisation-compliant) | Pilot to commercial | EU GMP, ISO 15378 |
| Analytical / QC Labs | Full-service (HPLC, GC-MS, NMR) | Method development to release | EU GMP, GLP, ISO 17025 |
Sources: PAIH 2025, Rezon Bio capabilities disclosure, Polpharma CDMO brochure, industry surveys Q4 2025.
Poland's pharmaceutical cost advantage is one of the sector's most compelling attributes for international buyers and partners. The savings are not marginal — across virtually all pharmaceutical service categories, Poland offers 30–45% lower costs compared to Germany and 40–60% compared to Switzerland, while maintaining identical regulatory standards under the EU GMP framework. This cost differential is structural rather than cyclical, driven by fundamentally lower labour costs (pharmaceutical scientists earn approximately 45–55% less than German equivalents), lower facility operating costs (GMP facility leases are 50–60% cheaper), and competitive utility and energy prices.
Critically, these cost advantages are achieved without quality compromises. Every pharmaceutical manufacturer in Poland operates under the same EU GMP requirements as their German or Swiss counterparts, subject to inspection by the same EMA framework. International buyers who have conducted quality audits of Polish pharma facilities consistently report quality systems, documentation practices, and manufacturing hygiene comparable to Western European sites. The cost advantage is purely a function of macroeconomic factors — wage levels, real estate costs, and general price levels — rather than any regulatory or quality differential.
The most significant driver of Poland's cost competitiveness is labour costs. A pharmaceutical scientist in Poland earns €28,000–38,000 per year (depending on experience and specialisation), compared to €55,000–75,000 in Germany and €80,000–110,000 in Switzerland. Quality assurance managers command €35,000–50,000 in Poland versus €65,000–90,000 in Germany. Manufacturing operators earn €18,000–25,000 compared to €35,000–50,000 in Germany. These differentials persist despite Poland's consistently high educational output — the country ranks 1st in CEE and 5th in all of Europe for the number of biopharma-related graduates, with over 39 universities offering biotech-related degree programmes. The talent pool is deep, multilingual (English proficiency in Poland is among the highest in Central Europe), and technically sophisticated.
For international buyers, the relevant metric is total cost of ownership (TCO), not simply unit price. Poland's TCO advantage versus Asian suppliers is often stronger than the headline unit cost comparison might suggest. While Indian or Chinese API prices may be 10–20% lower than Polish equivalents, the TCO calculation shifts when factoring in: transportation costs and lead times (1–3 days from Poland vs. 4–8 weeks from Asia by sea), import compliance costs (none within the EU single market vs. significant for third-country imports), inventory carrying costs (lower safety stock requirements with shorter supply chains), quality-related costs (lower rejection rates, fewer supply disruptions), IP protection costs (EU legal framework vs. often weaker enforcement in Asian jurisdictions), and communication efficiency (same time zone, cultural compatibility, English proficiency). For European-market products, Poland's TCO is frequently 15–25% lower than Asian alternatives when all factors are considered.
| Cost Category | Poland | Germany | Switzerland | India | Savings vs. DE |
|---|---|---|---|---|---|
| Pharma Scientist (annual) | €28–38K | €55–75K | €80–110K | €8–15K | 45–55% |
| QA Manager (annual) | €35–50K | €65–90K | €90–130K | €12–22K | 40–50% |
| GMP Facility Lease (€/m²/mo) | €8–14 | €18–28 | €30–50 | €3–8 | 50–60% |
| API Synthesis (per kg) | €800–2,500 | €1,500–4,500 | €2,200–6,000 | €400–1,500 | 35–50% |
| Tablet Mfg (per 1M units) | €3,000–6,000 | €5,500–10,000 | €8,000–14,000 | €1,500–3,500 | 40–55% |
| Biosimilar CDMO (cell→GMP) | €1.2–2.5M | €2.5–5.0M | €3.5–7.0M | €0.8–1.8M | 45–60% |
| Phase II Trial (per patient, onco) | €12–20K | €25–40K | €35–55K | €5–12K | 50–60% |
| Stability Study (ICH, 12-mo) | €15–25K | €30–50K | €40–65K | €8–15K | 45–55% |
| Regulatory Dossier (CTD Mod 3) | €20–40K | €45–80K | €60–100K | €10–25K | 50–55% |
| Bioanalytical Validation | €8–15K | €18–30K | €25–40K | €4–10K | 45–55% |
Sources: Hays Poland Salary Guide 2025, CDMO pricing benchmarks, CRO market intelligence, GIF data, industry surveys Q4 2025. Prices exclude VAT. India prices for reference; Indian facilities may not hold EU GMP/EMA certification. Actual costs vary by complexity and volume.
The quality assurance framework governing Poland's pharmaceutical industry is comprehensive, multi-layered, and fully aligned with European Union standards. At its foundation lies the EU GMP (Good Manufacturing Practice) system, which is mandatory for all pharmaceutical manufacturing in Poland and enforced through regular inspections by the Chief Pharmaceutical Inspectorate (Główny Inspektorat Farmaceutyczny, GIF). This framework ensures that every pharmaceutical product manufactured in Poland meets the same quality, safety, and efficacy standards as products from any other EU member state — a critical consideration for international buyers assessing supplier risk.
Beyond the mandatory EU GMP baseline, Polish pharmaceutical companies have increasingly adopted additional voluntary certifications to enhance their competitive position in international markets. ISO 9001:2015 (quality management systems) adoption among exporting pharma companies is estimated at 85–90%. For medical device manufacturers, ISO 13485:2016 is standard, with compliance enforced through Notified Bodies and Poland's Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL). Several leading manufacturers — including Polpharma's API division and Rezon Bio's Gdańsk facility — have additionally obtained US FDA certifications, enabling them to supply the American market and demonstrating an additional layer of quality assurance beyond EU requirements.
The EU GMP framework, codified in EudraLex Volume 4 and its associated annexes, establishes the baseline quality requirements for all pharmaceutical manufacturing in Poland. Key elements include: a comprehensive quality management system with documented quality policy and objectives; qualified person (QP) responsibility for batch certification and release; validated manufacturing processes with documented procedures; controlled environmental conditions (cleanrooms classified per EU GMP Annex 1 for sterile products); equipment qualification and calibration programmes; raw material and component testing and approval; in-process controls and finished product testing; stability programmes per ICH guidelines; deviation management and CAPA systems; change control procedures; and comprehensive documentation (batch records, SOPs, specifications). GIF conducts both routine and risk-based inspections, and GMP certificates are publicly available through the EMA's EudraGMDP database.
The certification landscape among Polish pharmaceutical exporters reflects a strategic approach to accessing international markets. FDA registration and cGMP compliance are held by approximately 15–20% of pharmaceutical companies, typically the larger manufacturers and CDMOs targeting US market access or serving multinational clients who require FDA-standard quality systems. ISO 14001:2015 (environmental management) adoption is growing rapidly, currently at 40–50% among larger manufacturers, driven by ESG requirements from international clients and EU sustainability directives. GLP (Good Laboratory Practice) compliance is mandatory for all facilities conducting non-clinical safety testing and is verified by the Polish Bureau for Chemical Substances. GDP (Good Distribution Practice) governs the distribution chain and is enforced by GIF, ensuring temperature-controlled storage and transport integrity throughout the pharmaceutical supply chain.
| Standard / Certification | Adoption Rate | Scope | How to Verify |
|---|---|---|---|
| EU GMP | 100% (mandatory) | All pharma manufacturing | EudraGMDP database (eudragmdp.ema.europa.eu) |
| ISO 9001:2015 | 85–90% | Quality management system | Accredited certification body certificate |
| ISO 13485:2016 | 90%+ (med. devices) | Medical devices QMS | Notified Body certificate; URPL registration |
| US FDA cGMP | 15–20% | US market compliance | FDA Establishment Registration (accessdata.fda.gov) |
| ISO 15378:2017 | 60–70% (packaging) | Primary pharma packaging | Accredited certification body |
| ISO 14001:2015 | 40–50% | Environmental management | Accredited certification body |
| GLP (OECD) | 100% (labs, mandatory) | Non-clinical safety testing | Polish Bureau for Chemical Substances |
| GDP | 100% (distrib., mandatory) | Pharma distribution | GIF inspection records |
Sources: GIF, EMA EudraGMDP, ISO Survey, PAIH 2025. Adoption rates estimated among pharma/biotech exporters, Q4 2025.
Looking for Polish pharmaceutical or biotech partners? Submit your requirements for matched supplier introductions.
Firma farmaceutyczna lub biotechnologiczna z Polski? Zwiększ eksport poprzez B2BPoland.
Poland's pharmaceutical and biotech sector is geographically distributed across several key regions, each with distinct specialisation profiles and supporting infrastructure. Unlike some European pharma markets that are concentrated in a single region, Poland's life sciences ecosystem is polycentric, offering international buyers and partners multiple options for collaboration depending on their specific technology requirements and logistics preferences.
The Warsaw metropolitan area serves as the administrative and business centre of Poland's pharmaceutical industry. It hosts the headquarters of major regulatory bodies (GIF, URPL, ABM), the largest concentration of CROs and regulatory affairs consultancies, and significant manufacturing capacity. Rezon Bio's Duchnice facility (near Warsaw) provides biologics CDMO services, while numerous pharma distribution companies are headquartered in the region. The Warsaw academic ecosystem — including the Medical University of Warsaw, Warsaw University of Technology, and the University of Warsaw — provides a deep talent pool for pharmaceutical R&D. The city's international connectivity (Warsaw Chopin Airport with direct flights to all major European capitals) makes it the most accessible location for international visitors.
The Gdańsk-Gdynia-Sopot metropolitan area (Tricity) has emerged as Poland's biologics manufacturing hub, anchored by Rezon Bio's EMA-certified, FDA-approved Gdańsk facility. The region benefits from the presence of the Medical University of Gdańsk and the Gdańsk University of Technology, both active in life sciences research. The Tricity area also hosts a growing cluster of biotech startups and pharmaceutical companies, supported by the Pomeranian Science and Technology Park and the Gdańsk Science and Technology Park. Port access via the Port of Gdańsk provides additional logistics flexibility for international supply chains.
Wrocław and the Lower Silesia region host a diverse life sciences ecosystem with strength in biotech innovation, diagnostics, and pharmaceutical R&D. Pure Biologics, headquartered in Wrocław, specialises in the discovery and development of innovative biologic drugs and extracorporeal therapies, with a focus on immuno-oncology, autoimmunology, and rare neurological diseases. The city's vibrant academic environment (University of Wrocław, Wrocław University of Science and Technology, Wrocław Medical University) supports talent development, while the EIT Health InnoStars programme has recognised the region's innovation potential. Wrocław's recognition as a top mid-sized European city of the future (fDi Intelligence 2024) underscores its attractiveness for business operations.
The Łódź region hosts significant pharmaceutical manufacturing and biotech capabilities. Mabion's biologics manufacturing facility in Konstantynów Łódzki (near Łódź) is a key asset for Poland's biosimilar development programme. The Copernicus Memorial Hospital in Łódź has been pioneering AI-driven radiology programmes. The Łódź Special Economic Zone provides incentives for pharmaceutical investments, and the Medical University of Łódź is an important source of clinical research talent.
Kraków and Małopolska host several important pharma and biotech companies, including Selvita (now part of the Ryvu Therapeutics ecosystem) and the Jagiellonian University's strong life sciences faculty. The Silesia region contributes manufacturing capacity with competitive cost structures and excellent logistics connectivity. Poznań and Wielkopolska are home to genXone (nanopore sequencing specialist) and support pharmaceutical supply chain operations. The diverse regional footprint ensures that international buyers can find suitable partners regardless of their specific technology requirements or preferred logistics corridors.
Poland's pharmaceutical and biotechnology sector is poised for sustained growth over the coming years, driven by a confluence of structural, policy, and market factors that favour the continued expansion of manufacturing capabilities, R&D investment, and export volumes. The sector's growth trajectory outpaces Poland's overall economic expansion, and several macro trends — European supply chain diversification, increasing demand for biosimilars, digital health adoption, and the growing importance of precision medicine — create a favourable environment for Polish pharma companies and their international partners.
The post-COVID-19 push to diversify pharmaceutical supply chains away from excessive reliance on Asian manufacturing has been one of the most significant drivers of investment in Polish pharmaceutical infrastructure. The EU's Pharmaceutical Strategy explicitly encourages onshoring of critical pharmaceutical manufacturing capabilities, and Poland — with its combination of EU membership, competitive costs, and established manufacturing base — is a primary beneficiary of this trend. The launch of Rezon Bio in 2025 as a dedicated European CDMO for biologics, explicitly positioning itself as a cost-competitive European alternative to Asian CDMOs, exemplifies this strategic direction.
The global biosimilar market continues to expand rapidly as originator biologic patents expire, and Poland is well-positioned to capture an increasing share of both development and manufacturing activity. Polish companies are advancing biosimilar programmes across multiple therapeutic areas, and CDMO capabilities for monoclonal antibodies, recombinant proteins, and cell-based therapies are being scaled. The Eastern European advocacy for shorter patent periods during Poland's EU presidency (influencing the EU pharmaceutical reform debate) could further accelerate biosimilar market access.
Artificial intelligence is increasingly embedded across the Polish pharmaceutical value chain — from drug discovery (Ardigen's AI-driven CRO platform, Selvita's computational chemistry capabilities) to diagnostics (BrainScan's AI radiology, Scope Fluidics' microfluidic diagnostics) and manufacturing process optimisation. According to the Top Disruptors in Healthcare 2024 report, 64% of Polish healthcare startups are developing AI and machine learning applications. The digital health segment is expected to accelerate further, supported by government initiatives and EU funding under the Recovery and Resilience Facility.
The investment landscape for Polish pharma and biotech continues to strengthen. Venture capital flows into the healthcare sector account for 25% of total Polish VC investment, a proportion that has been increasing year-on-year. The European Investment Bank has provided financing to companies including Ryvu Therapeutics, and the National Centre for Research and Development (NCBR) offers grants for pharmaceutical R&D projects. Several Polish biotech companies are publicly listed on the Warsaw Stock Exchange, providing access to growth capital and liquidity for early investors. The combination of public and private funding sources creates a supportive environment for both early-stage innovation and scale-up of proven technologies.
This comprehensive guide synthesises information from Polish government agencies, industry associations, manufacturer interviews, international client surveys, and market research. While every effort has been made to ensure accuracy, specific vendor capabilities, pricing, technology expertise, and market conditions evolve continuously. Prospective clients should conduct independent vendor evaluation, technical assessments, reference checks, and commercial negotiations before pharmaceutical sourcing commitments.
Polish Investment and Trade Agency (PAIH) — The Pharmaceutical & Medical Devices Sector Report 2025 (paih.gov.pl); Central Statistical Office of Poland (GUS) — National industry statistics, innovation data, employment figures (stat.gov.pl); Chief Pharmaceutical Inspectorate (GIF) — GMP certificates, inspection data, manufacturing authorisations (gif.gov.pl); Polish Agency for Enterprise Development (PARP) — Medical Devices and Pharma Sector in Poland Report 2024 (parp.gov.pl); Polish Medical Research Agency (ABM) — Clinical trial funding and oversight (abm.gov.pl); Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) — Product registration data (urpl.gov.pl).
INFARMA — Employers' Union of Innovative Pharmaceutical Companies (infarma.pl); BioForum/CEBioForum — Association of Biotechnology Companies (cebioforum.com); POLMED — Polish Chamber of Commerce of Medical Devices (polmed.org.pl); TECHNOMED — Medical Industry Organisation; Polish Chamber of Commerce (Krajowa Izba Gospodarcza, KIG).
Statista — Pharmaceutical Industry in Poland (2025); IBISWorld — Pharmaceutical Product & Preparations Manufacturing in Poland (2026); IQVIA — Polish pharmaceutical market data; International Trade Centre — Trade statistics; Hays Poland — Salary Guide 2025; PFR Ventures — Polish VC Market Outlook; EY — European Attractiveness Survey 2024; Top Disruptors in Healthcare 2024 Report.
EudraLex Volume 4 (EU GMP); ICH Guidelines Q7, Q8, Q9, Q10; ISO 9001:2015, ISO 13485:2016, ISO 15378:2017, ISO 14001:2015, ISO 50001:2018; EU MDR 2017/745; EU IVDR 2017/746; FDA 21 CFR Parts 210/211; OECD GLP Principles; EU GDP Guidelines 2013/C 343/01.
Manufacturer capability surveys (Q4 2025); International buyer interviews and procurement benchmarking; CDMO pricing analysis and competitive intelligence; Industry event insights from CPhI Worldwide, BioConvention, CEBioForum 2025, Nordic Life Science Days (NLSDays). Company disclosures: Polpharma, Rezon Bio, Mabion, Ryvu Therapeutics, Adamed public filings and press releases.
Access our directory of EU GMP certified pharmaceutical manufacturers or submit your sourcing requirements.